Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial

Kuan Pin Su, Shih Yi Huang, Chih Chiang Chiu, Winston W. Shen

Research output: Contribution to journalArticle

396 Citations (Scopus)

Abstract

Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume13
Issue number4
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Major Depressive Disorder
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Placebos
Depression
Eicosapentaenoic Acid
Docosahexaenoic Acids
Erythrocytes
Cell Membrane
Therapeutics

Keywords

  • Diet
  • Fish intake
  • Major depressive disorder
  • Nutrition therapy
  • Omega-3 polyunsaturated fatty acids
  • Taiwan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Omega-3 fatty acids in major depressive disorder : A preliminary double-blind, placebo-controlled trial. / Su, Kuan Pin; Huang, Shih Yi; Chiu, Chih Chiang; Shen, Winston W.

In: European Neuropsychopharmacology, Vol. 13, No. 4, 08.2003, p. 267-271.

Research output: Contribution to journalArticle

@article{40e4cb43ebcd417290ac302006f81bdb,
title = "Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial",
abstract = "Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P",
keywords = "Diet, Fish intake, Major depressive disorder, Nutrition therapy, Omega-3 polyunsaturated fatty acids, Taiwan",
author = "Su, {Kuan Pin} and Huang, {Shih Yi} and Chiu, {Chih Chiang} and Shen, {Winston W.}",
year = "2003",
month = "8",
doi = "10.1016/S0924-977X(03)00032-4",
language = "English",
volume = "13",
pages = "267--271",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Omega-3 fatty acids in major depressive disorder

T2 - A preliminary double-blind, placebo-controlled trial

AU - Su, Kuan Pin

AU - Huang, Shih Yi

AU - Chiu, Chih Chiang

AU - Shen, Winston W.

PY - 2003/8

Y1 - 2003/8

N2 - Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P

AB - Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P

KW - Diet

KW - Fish intake

KW - Major depressive disorder

KW - Nutrition therapy

KW - Omega-3 polyunsaturated fatty acids

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=0042850504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042850504&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(03)00032-4

DO - 10.1016/S0924-977X(03)00032-4

M3 - Article

C2 - 12888186

AN - SCOPUS:0042850504

VL - 13

SP - 267

EP - 271

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 4

ER -